What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 6 months ago
WATCH: Severe Hematologic Relapse Risk in SLE
Dr. Kathryn Dao ( @KDAO2011) discusses POS0365 presented at the #EULAR2022 meeting.
https://t.co/a0LgsEZ0w4 https://t.co/Ajl22OIHxD
Dr. John Cush RheumNow
3 years 6 months ago
Topical therapies take centre stage
Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. #EULAR2022
https://t.co/V9plk1vAEd https://t.co/fyNWWtconi
Impressive data on novel treatment for SLE were presented at the EULAR22 Congress. A disease that is difficult to study due to its pleomorphic presentation, unpredictable disease course, and high mortality rates, SLE is considered the dragon of all autoimmune diseases. Here are highlights of four exciting abstracts presented at the meeting with emerging therapeutics designed to slay the beast.
Laurent ARNAUD Lupusreference
3 years 6 months ago
🆒 Couldn't attend my #EULAR2022 talk about the role of #twitter in #Rheumatology?
Check the 2 slides below summarizing the role of #socialmedia for the dissemination of medical information. #TwitterRheum
⬇️ BEFORE vs AFTER Twitter ⬇️ https://t.co/ZzVdoWYEMr
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Updates on Axial SpA from #EULAR2022 @RheumNow https://t.co/0dGPUpksxT
Dr Ai Lyn Tan DrAiLynTan
3 years 6 months ago
EULAR recommendations for management of #RheumatoidArthritis
6️⃣Glucocorticoids should be tapered & discontinued as soon as clinically feasible
8️⃣JAKi can be used but consider risk factors
via Prof Smolen #EULAR2022 https://t.co/7cocPSpgkH
Janet Pope Janetbirdope
3 years 6 months ago
#good news and bad news. Avacopan works v well for steroid sparing in #GPA. It’s an oral C5a receptor blocker - maintains more remission and less relapses and less total prednisone OP0180 @eular_org #EULAR2022 @RheumNow Bad news $$💰 will limit access.
Janet Pope Janetbirdope
3 years 6 months ago
#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/kTn4rxMlej
Dr. John Cush RheumNow
3 years 6 months ago
Watch: #EULAR2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
https://t.co/B7AYkTnAe0 https://t.co/NF3f6AFv6K
Dr. John Cush RheumNow
3 years 6 months ago
Update on Axial SpA at #EULAR2022
This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA).
Dr Antoni Chan shares his picks of abstracts from the conference.
https://t.co/AhUC7ORrZi https://t.co/1olLoNS5Ey
Dr. John Cush RheumNow
3 years 6 months ago
#EULAR2022 – Day 4 Report
Check out our my favorite late-breakers from Day 4.
https://t.co/R0hPetOos4 https://t.co/T57XRIKZs5
Dr. John Cush RheumNow
3 years 6 months ago
Spondyloarthritis and COVID-19
With the availability of vaccines and new therapeutics, many of our patients are fully vaccinated. We know this can limit their chances of severe COVID all while allowing their rheumatic disease to be treated. #EULAR2022
https://t.co/PmQNKYg1Ao https://t.co/N4DJVYJqrL
Poster Hall